Axsome Therapeutics Stock Analysis

AXSM Stock  USD 128.33  1.24  0.98%   
Axsome Therapeutics is undervalued with Real Value of 139.97 and Target Price of 131.18. The main objective of Axsome Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Axsome Therapeutics is worth, separate from its market price. There are two main types of Axsome Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Axsome Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Axsome Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Axsome Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Axsome Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 6.04. Axsome Therapeutics had not issued any dividends in recent years. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people. For more info on Axsome Therapeutics please contact Herriot MD at (212) 332-3241 or go to https://www.axsome.com.

Axsome Therapeutics Investment Alerts

Axsome Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 385.69 M. Net Loss for the year was (287.22 M) with profit before overhead, payroll, taxes, and interest of 352.39 M.
Axsome Therapeutics currently holds about 73.39 M in cash with (128.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Over 78.0% of the company shares are held by institutions such as insurance companies
Latest headline from gurufocus.com: Axsome Therapeutics Inc Announces Participation in Upcoming Investor Conferences

Axsome Therapeutics Upcoming and Recent Events

20th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Axsome Largest EPS Surprises

Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-08-08
2018-06-30-0.29-0.32-0.0310 
2016-05-11
2016-03-31-0.28-0.31-0.0310 
2017-08-09
2017-06-30-0.34-0.30.0411 
View All Earnings Estimates

Axsome Therapeutics Environmental, Social, and Governance (ESG) Scores

Axsome Therapeutics' ESG score is a quantitative measure that evaluates Axsome Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Axsome Therapeutics' operations that may have significant financial implications and affect Axsome Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Axsome Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Alethea Capital Management, Llc2024-12-31
734.3 K
Amvescap Plc.2024-12-31
692.5 K
Wellington Management Company Llp2024-12-31
673.2 K
Perceptive Advisors Llc2024-12-31
664.1 K
Hood River Capital Management Llc2024-12-31
644.8 K
Morgan Stanley - Brokerage Accounts2024-12-31
576.9 K
Lazard Asset Management Llc2024-12-31
537.7 K
Sofinnova Ventures2024-12-31
491.7 K
Partner Fund Management Lp2024-12-31
467.4 K
Rtw Investments, Llc2024-12-31
4.1 M
Vanguard Group Inc2024-12-31
3.9 M
Note, although Axsome Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Axsome Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.26 B.

Axsome Profitablity

The company has Profit Margin (PM) of (0.74) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.52) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.52.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.56)(0.59)
Return On Capital Employed(0.83)(0.87)
Return On Assets(0.51)(0.53)
Return On Equity(5.04)(4.79)

Management Efficiency

Axsome Therapeutics has return on total asset (ROA) of (0.2728) % which means that it has lost $0.2728 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.3163) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of February 2025, Return On Tangible Assets is likely to drop to -0.59. In addition to that, Return On Capital Employed is likely to drop to -0.87. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 27th of February 2025, Intangibles To Total Assets is likely to grow to 0.15, while Return On Tangible Assets are likely to drop (0.59).
Last ReportedProjected for Next Year
Book Value Per Share 1.19  1.00 
Tangible Book Value Per Share(0.04)(0.04)
Enterprise Value Over EBITDA(14.01)(14.71)
Price Book Value Ratio 71.10  74.66 
Enterprise Value Multiple(14.01)(14.71)
Price Fair Value 71.10  74.66 
Enterprise Value3.9 B4.1 B
Leadership at Axsome Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Operating Margin
(0.52)
Profit Margin
(0.74)
Beta
1.049
Return On Assets
(0.27)
Return On Equity
(2.32)

Technical Drivers

As of the 27th of February, Axsome Therapeutics shows the Risk Adjusted Performance of 0.1035, mean deviation of 2.7, and Downside Deviation of 2.31. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 128.33 per share. Given that Axsome Therapeutics has jensen alpha of 0.522, we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Axsome Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Axsome Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Axsome Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Axsome Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Axsome Therapeutics Outstanding Bonds

Axsome Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Axsome Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Axsome bonds can be classified according to their maturity, which is the date when Axsome Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Axsome Therapeutics Predictive Daily Indicators

Axsome Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Axsome Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Axsome Therapeutics Corporate Filings

F4
25th of February 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
18th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
14th of February 2025
Other Reports
ViewVerify
8K
10th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
31st of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
13th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
6th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
30th of December 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Axsome Therapeutics Forecast Models

Axsome Therapeutics' time-series forecasting models are one of many Axsome Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Axsome Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Axsome Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Axsome Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Axsome shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Axsome Therapeutics. By using and applying Axsome Stock analysis, traders can create a robust methodology for identifying Axsome entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.74)(0.78)
Operating Profit Margin(0.73)(0.76)
Net Loss(0.74)(0.78)
Gross Profit Margin 0.91  0.72 

Current Axsome Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Axsome analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Axsome analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
131.18Strong Buy17Odds
Axsome Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Axsome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Axsome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Axsome Therapeutics, talking to its executives and customers, or listening to Axsome conference calls.
Axsome Analyst Advice Details

Axsome Stock Analysis Indicators

Axsome Therapeutics stock analysis indicators help investors evaluate how Axsome Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Axsome Therapeutics shares will generate the highest return on investment. By understating and applying Axsome Therapeutics stock analysis, traders can identify Axsome Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow386.2 M
Long Term Debt180.7 M
Common Stock Shares Outstanding47.9 M
Total Stockholder Equity57 M
Tax Provision85 K
Property Plant And Equipment Net5.4 M
Cash And Short Term Investments315.4 M
Cash315.4 M
Accounts Payable72 M
Net Debt-123.8 M
50 Day M A102.5427
Total Current Liabilities230.1 M
Other Operating Expenses666.3 M
Non Current Assets Total83.4 M
Non Currrent Assets Other19.1 M
Stock Based Compensation85.2 M
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.04)
Revenue Per Share
8.05
Quarterly Revenue Growth
0.66
Return On Assets
(0.27)
Return On Equity
(2.32)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.